Evaluating Postmarket Vaccine Safety—Time to Consolidate This Mission at a Single Agency-Reference-Cited by-同舟云学术

Evaluating Postmarket Vaccine Safety—Time to Consolidate This Mission at a Single Agency

Published:2021-04-29 Issue:4 Volume:2 Page:e211236
ISSN:2689-0186
Container-title:JAMA Health Forum
language:en
Short-container-title:JAMA Health Forum

Author:

Gottlieb Scott¹

Affiliation:

1. American Enterprise Institute, Washington, DC

Publisher

American Medical Association (AMA)

Subject

General Earth and Planetary Sciences,General Environmental Science

Link

https://jamanetwork.com/channels/health-forum/articlepdf/2779572/gottlieb_2021_jf_210021_1619630987.48414.pdf

Reference8 articles.

1. Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS).;Shimabukuro;Vaccine,2015

2. Results from the first decade of research conducted by the Research on Adverse Drug Events and Reports (RADAR) project.;McKoy;Drug Saf,2013

3. Real-world evidence and real-world data for evaluating drug safety and effectiveness.;Corrigan-Curay;JAMA,2018

4. Harnessing scientific literature reports for pharmacovigilance: prototype software analytical tool development and usability testing.;Sorbello;Appl Clin Inform,2017

5. Successful comparison of US Food and Drug Administration sentinel analysis tools to traditional approaches in quantifying a known drug-adverse event association.;Gagne;Clin Pharmacol Ther,2016

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preventive Pharmacovigilance: timely and precise prevention of adverse events through person-level patient screening and dose-level product surveillance;Pharmaceutical Research;2023-06-22